IP Library Granted Patent US 8,875,716
Granted Patent B2
US 8,875,716 · App. 13/579,381 · Granted Nov 4, 2014

Oral smokeless tobacco products and oral smokeless non-tobacco snuff products comprising carbamide or carbamide salts

Inventors: Herman Norström (Gothenburg, SE); Dowen Birkhed (Gothenburg, SE)
Assignee: Swedish Match North Europe AB
A24B13/00A24B15/287A24B15/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,875,716
App. No.
13/579,381
Granted
Nov 4, 2014
Kind
B2
Abstract

Oral smokeless tobacco products and oral smokeless non-tobacco snuff products include carbamide or carbamide salt(s). The carbamide salt is chosen from the group including carbamide calcium sulphate [4(CH 4 N 2 O).CaSO 4 ], carbamide magnesium sulphate [6(CH 4 N 2 O).MgSO 4 .2H 2 O] and carbamide sodium chloride [CH 4 N 2 O).NaCl.H 2 O]. Moreover, carbamide or carbamide salt(s) are used in the manufacturing of oral smokeless tobacco products or oral smokeless non-tobacco snuff products.

Claims (8)

1. An oral smokeless tobacco product, comprising tobacco and a carbamide salt, wherein said oral smokeless tobacco product is in a smokeless form selected from the group consisting of moist tobacco snuff, or snus, chewing tobacco, oral dry tobacco snuff, and hard tobacco snuff, and wherein the oral smokeless tobacco product comprises a carbamide salt selected from the group consisting of carbamide calcium sulphate 4(CH 4 N 2 O).CaSO 4 , carbamide magnesium sulphate 6(CH 4 N 2 O).MgSO 4 2H 2 O, and carbamide sodium chloride CH 4 N 2 O).NaCl.H 2 O.

2. The oral smokeless tobacco product according to claim 1 , wherein the carbamide portion of the carbamide salt is present in an amount of from 0.1 mg/g to 200 mg/g of the final product.

3. The oral smokeless tobacco product according to claim 1 , wherein the carbamide portion of the carbamide salt is present in an amount of from 0.5 to 60 mg/g of the final product.

4. The oral smokeless tobacco product according to claim 1 , wherein the carbamide portion of the carbamide salt is present in an amount of from 2.5 to 20 mg/g of the final product.

5. An oral smokeless nontobacco snuff product, comprising nontobacco plant materials and a carbamide salt, wherein the oral smokeless non-tobacco snuff product is in a smokeless form selected from the group consisting of moist non-tobacco snuff, or snus, non-tobacco chew resembling chewing tobacco, oral dry non-tobacco snuff, and hard non-tobacco snuff, and wherein the oral smokeless non-tobacco product comprises a carbamide salt selected from the group consisting of carbamide calcium sulphate 4(CH 4 N 2 O).CaSO 4 , carbamide magnesium sulphate 6(CH 4 N 2 O).MgSO 4 .2H 2 O, and carbamide sodium chloride CH 4 N 2 O).NaCl.H 2 O.

6. The oral smokeless non-tobacco product according to claim 5 , wherein the carbamide portion of the carbamide salt is present in an amount of from 0.1 mg/g to 200 mg/g of the final product.

7. The oral smokeless non-tobacco product according to claim 5 , wherein the carbamide portion of the carbamide salt is present in an amount of from 0.5 to 60 mg/g of the final product.

8. The oral smokeless non-tobacco product according to claim 5 , wherein the carbamide portion of the carbamide salt is present in an amount of from 2.5 to 20 mg/g of the final product.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2012
From: NORSTROM, HERMAN; BIRKHED, DOWEN
To: SWEDISH MATCH NORTH EUROPE AB
Reel/Frame 029238/0943 →
Priority Claims (1)
SE 1000154 · Feb 17, 2010 · national
Continuity (2)
Provisional Application 61305432 · Feb 17, 2010
Related Publication 20130053603A1 · Feb 28, 2013